Pneumococcal conjugate second or third-dose vaccines (PCVc) in Iraq
Iraq: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 82.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Iraq, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Iraq stood at 82.0%. That is the highest value across all 18 years on record.
That represents a change of up 26.2% on the previous year.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Iraq peaked at 82.0% in 2025 and was at its lowest, 0.0%, in 2008.
Iraq ranks 106th of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Iraq, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 33.0% | — |
| 2018 | 33.0% | +0.0% |
| 2019 | 37.0% | +12.1% |
| 2020 | 0.0% | -100.0% |
| 2021 | 0.0% | — |
| 2022 | 0.0% | — |
| 2023 | 14.0% | — |
| 2024 | 65.0% | +364.3% |
| 2025 | 82.0% | +26.2% |
Iraq compared with similar countries
- Iraq's 82.0% is above the median for upper middle income countries, which is 76.0%, 1.1× the median. (57 countries reporting)
- Iraq's 82.0% is below the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 90% of the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 10.3% | 0.0% | 37.0% | 10 |
| 2020s | 26.8% | 0.0% | 82.0% | 6 |
Countries ranked near Iraq
More health data for Iraq
- Un projection of annual infant deaths, annual growth rate -1.4 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.9773 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 898.9 deaths per 1,000 people (2090)
- Number of infants who die before age 1 5,830 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.988 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0587 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.9818 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Iraq?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Iraq was 82.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Iraq?
- The highest recorded value was 82.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Iraq?
- The lowest recorded value was 0.0% in 2008.
- How does Iraq rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iraq ranks 106th out of 194 countries with data for 2025.
- Where does this Iraq data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).